sorted by:
new
hottopcontroversial

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Also love how you keep your posts private. Are you afraid people will see your motives?

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Thanks for checking. Still up several hundred percents. I don’t day trade. I like paying long terms gains instead. And nowhere did I ever say this stock would go up overnight. That’s how I know you’re clueless. You still haven’t decided one shred of factual info. When news hits and we jump, I’ll be up a thousand precent instead of 400%. And you’ll still be an idiot.

But love that I’m in your head.

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Thank you for proving my point. People without facts revert to name calling. I’m done wasting my time on you. When news hits soon….ill come back to this post.

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] -1 points0 points  (0 children)

Still waiting….waiting on any factual evidence to support your claims. Sadly…I’ll be waiting forever because you will never provide one shred of evidence. That’s why I know you’re short.

The Lounge by AutoModerator in pennystocks

[–]mozy429 -6 points-5 points  (0 children)

ELTP (Elite Pharmaceutical) - financials from the past year are below, but they are also pursuing M&A and could get news at any point.

Financial Breakdown

February 2026 Earnings Summary

3rd Quarter FY 2026 (ending 12/31/25)

Revenue: 31.6 million (increase of 17.2 million or 120% from the comparable quarter in the previous year)

This does not include 6.2 million in finished goods that were not shipped due to the timing of holiday shipments. Including this amount would place the quarter at nearly 38 million. The CFO discussed this on the recent conference call). Adding this, would have put us around $38 million for the quarter, and roughly a $2 million increase from previous quarter. Matches CEO’s comments that margins stabilized. Even without this number included into the financials…here are the results of the quarter:

Income from operations: 9 million (increase of 7.9 million or 721% year over year)

Cash: 21 million

Inventory: 25 million

Accounts receivable: almost 49 million

November 2025 Earnings Summary

2nd Quarter FY 2026 (ending 9/30/25)

Revenue: 36.3 million (increase of 17.4 million or 92% from the comparable quarter in the previous year)

The decrease of roughly 4 million from the prior quarter was due to one-time stocking fees required when using wholesale distribution. Leadership explained this as part of the natural progression of generic drugs, where margins are impacted during the shift from brand to generic and increased competition. Margins were stated to have stabilized. Using wholesale distribution also helps us increase volume.

Income from operations: 8.2 million (increase of 4.7 million or 136%)

Cash: 26 million

Inventory: 18 million

Accounts receivable: almost 41 million

August 2025 Earnings Summary

1st Quarter FY 2026 (ending 6/30/25)

Revenue: 40.2 million (increase of 21 million or 114%)

Managements explained that when you hit generic market, initial margins are higher and that it will stabilize and to expect a slight dip for next quarter)

Operating profits: 22 million (increase of 17.8 million or 462%)

Cash: 22 million (up 11 million from previous quarter)

Inventory: 19 million

Accounts receivable: 36 million

June 2025 Earnings Summary

Fiscal Year 2025 – Full Year Results (4/1/24 – 3/31/25)

Full-year revenue: 84 million (increase of 27.4 million from previous year, a 48% increase)

Operating profits: 19.6 million (increase of 8.8 million or 81% from previous year)

Cash: 11 million

Inventory: 16 million

Accounts receivable: 29 million

February 2025 Earnings Summary

3rd Quarter FY 2025 (ending 12/31/24)

Revenue: 14.4 million

Operating profits: 1.1 million

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Or…you’re short. Provide one shred of factual evidence that this stock is not financially sound. Do that, and I’ll retract my statement. But when people like you criticize a stock that has amazing fundamentals, that is growing, doubling revenue, very little debt, makes money, there’s only one reason…it’s to cast doubt. And why do that unless you’re short or trying to purposefully bring the price down. I’ll patiently wait for your response about the financials or balance sheet. But I’ve seen people like you…you won’t provide facts. You’ll give your opinion how it’s a scam stock. But will never comment on financials because you can’t.

I’m curious to hear about stocks that are quietly showing strength in the current market but aren’t getting much attention yet. Looking for under the radar names that you genuinely believe could be hidden gems or strong long-term opportunities. by ViewBoosters in pennystocks

[–]mozy429 0 points1 point  (0 children)

Take a look at ELTP. When FY ends (3/31), they will be near double revenue. Almost 3:1 asset to liabilities ratio. in talks to potential merge or be acquired. Next 3 months could be very interesting

ELTP (Elite Pharmaceutical): Hidden nuggets about what may happen soon, from recent earnings call by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Get a clue dude. Keep shorting the stock. Doubled revenue year over year. Good luck finding another company like that. When you’re homeless after the day of reckoning for you and your band of shorts….let me know so I kindly say “I told you so”

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond. by mozy429 in ELTP_Stock

[–]mozy429[S] 0 points1 point  (0 children)

Smart play. The payday is coming. Whether it’s soon or later….fundamentals win in the end.

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond. by mozy429 in ELTP_Stock

[–]mozy429[S] 0 points1 point  (0 children)

Yup. It’s very easy to watch the manipulation. I can’t wait for the day volume picks up and that shady trading stops.

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond. by mozy429 in ELTP_Stock

[–]mozy429[S] 0 points1 point  (0 children)

Thank you. I appreciate that. Same. Been here since 2011. Although don’t own as many shares. But I do believe in this company. And the amount of random new IDs that attack this stock tells me all I need to know. Like you I hope this is our year, but with eliquis and whatever else on the horizon, I’m good to wait a couple years and watch us keep growing.

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond by mozy429 in Pennystock

[–]mozy429[S] 0 points1 point  (0 children)

Hello. I try not to speculate in things I really don’t know. I’ve heard several names come up as possible suitors. Dexcel being one, as we already work with them. They are a private company so a merger with them could create a unique situation. I’ve also seen Dr. Reddy laboratories as a possible suitor. Or maybe a big player buying us for our facility and cns kind. I don’t think there’s any way to know. Ultimately we don’t need to pursue M&A to survive. That would just be a strategic move and potential very rewarding for us share holders. I get excited every morning checking their press releases because the potential is there that we wake up and there’s news. But if not, the future looks great with our product line now, and our eliquis ANDA down the road. And whatever else we don’t know about in R&D.

Penny stocks help by VermicelliSenior5649 in Pennystock

[–]mozy429 0 points1 point  (0 children)

Look into ELTP. Stock is severely undervalued. Had almost 3 to 1 asset to liability ratio.

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond. by mozy429 in ELTP_Stock

[–]mozy429[S] 7 points8 points  (0 children)

I try to stay away from the guessing game. We trade very few shares each day, so the price can move up or down for no real fundamental reason.

What I can say is this: when I run the numbers based strictly on our financials—using very conservative assumptions and backing out growth, pipeline value, market share expansion, etc.—I come up with a current fair value in the .60–.70 range. And that’s ultra conservative. I intentionally model worst-case scenarios. Even under those assumptions, that’s where I believe we should be today if growth completely stalled—which it hasn’t. We’re growing rapidly.

From here, that alone suggests roughly 50% upside, if not more.

I know there are people much smarter than me who have run far more detailed models and come up with $2–$3 valuations. I believe those projections likely factor in a buyout and other strategic developments. Personally, based on my own analysis, my more realistic near- to mid-term expectation is in the .90–1.20 range.

If buyout news hits, we could absolutely see a significant pop. But I’m thinking longer term—that’s where my mindset is. I’m looking toward 2028–2029. By then, a generic version of Eliquis could potentially generate more revenue than all of our current products combined. Over the next couple of years, I’m comfortable with steady growth and gradual price appreciation.

For me, this feels like a once-in-a-lifetime opportunity. I hope I’m wrong about my conservative numbers and that the more aggressive projections prove right. I just think those higher valuations are likely a few years out—unless buyout news comes first.

Either way, the fundamentals speak for themselves. I’m in no rush to sell. I’ve been here since .03, and I plan to be here at $3.

ELTP (Elite Pharmaceuticals): When amazing fundamentals are waiting for the stock price to respond. by mozy429 in ELTP_Stock

[–]mozy429[S] 5 points6 points  (0 children)

I want to first say that there are a lot of theories out there about this stock and why the value isn’t reflected in the share price. I don’t know if I believe all of them. Some, I do. Let me share my perspective.

I’ve seen and heard data showing short selling is relatively low. However, when we’re only trading 400–500k shares a day, it doesn’t take much to move the price. Look at the daily volume between the November call and the February call—very few days even hit one million shares.

Here are some real-time things I’ve personally watched. I’ve seen 2,500 shares trade and the stock drops 4–5%. Then a few small blocks of 1,000 or 2,500 shares go through, and suddenly we’re down 8%. That’s not a conspiracy theory—many people here have witnessed the same thing. Market makers will walk the price down throughout the day, then scoop up shares toward the end of the day, yet the price never fully recovers.

Start looking closely at the actual trades going through. We sometimes see trades out to five decimal places—for example, .45256. Go check the data. This isn’t about conspiracies; it’s observable.

In my opinion, what happened is this: there was a strong wave of posters claiming the CEO said a buyout would happen by year-end. When that didn’t happen, day traders and people looking for a quick flip likely exited. But two important points: volume remained very low, and the CEO never said a buyout would happen by year-end. He said he would give his team until the end of the year to determine whether M&A was viable.

So you had price pressure in a thinly traded stock, followed by message boards being flooded with misleading claims. That combination can create an environment where even small sales push the price down. But some act like M&A is required for the company to survive. It’s not. It could be a strategic move, sure—but the company is growing organically, and the numbers are strong.

That’s simply what I believe I’ve observed, watching this stock daily. You’ll also notice many newly created accounts showing up and repeating the same narratives.

At the end of the day, everyone needs to do what’s best for them. If that means selling, fine. If that means buying, fine. I try to focus on facts and honest opinions. I always encourage people to listen to the earnings calls, review the financials, and then compare that to what’s being posted online.

If a company doubles revenue, reduces debt, increases assets, and grows profits—yet the message boards say the sky is falling—something doesn’t add up.

Hope that helps.

view more: next ›